Clinical Trial Update: Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for CAN103 in Gaucher disease (Type 1 and Type 3) by CANbridge.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type
• Gaucher Disease Type 3

Drugs mentioned

• CAN103

Snippet

Sponsor: CANbridge (Suzhou) Bio-pharma Co., Ltd. | Conditions: Gaucher Disease, Type 1, Gaucher Disease, Type 3 | Phase 1, Phase 2 | Status: UNKNOWN